IND Programs

Charles River has proven experience with IND-enabling studies and with getting our clients’ investigational new drugs to market. With a unique range of services and best-in-class expertise, we help clients successfully initiate and complete their IND-enabling program on time and within budget. And, as a global CRO, we can leverage this same experience to design suitable studies or programs for submission to regulatory authorities around the world.

Custom IND Studies

We work with clients to customize each exploratory IND-enabling study program based upon the type of drug, its intended route of administration, and its clinical indication. We can also guide the steps leading up to the program’s implementation, including the drug metabolism and pharmacokinetic evaluations needed to inform candidate selection.


Resources for Your IND Program

Scientist in a lab.

From regulatory insight to a milestone map, find everything you need for planning successful IND-enabling studies. Open the Toolbox


As the success of an IND program relies as much upon the planning as the execution, every program is overseen and carried out by scientists and program management professionals who are dedicated to both discovery and development. This allows lead candidate selection to flow seamlessly into development. With a deep understanding of investigational new drug programs and Charles River’s comprehensive portfolio of services, our teams can create custom solutions for our clients.

New SEND Guidance Notice:

As of July 15, 2020, the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) has released a Federal Register Notice announcing the requirement of support of CDISC Standard for the Exchange of Nonclinical Data (SEND). Learn More


American College of Toxicology (ACT) Annual Meeting Resources

Virtual attendees at American College of Toxicology (ACT) Annual Meeting.

Although this year’s ACT Annual Meeting was virtual, our experts presented several continuing education sessions, symposiums, exhibitor sessions, and posters throughout the week. Explore our resources to download presentations, poster recordings, and other content. Download Now


 

Capabilities and Support

Need Guidance on Your IND-Enabling Program?

Ask an Expert


Integrated Drug Discovery Seminar Series

Virtual attendees at the Integrated Drug Discovery Seminar Series.

Charles River is offering a series of seminars on how to use an Integrated Drug Discovery (IDD) approach to reduce time to clinic.
Request a Seminar


 

Frequently Asked Questions (FAQs) for IND-Enabling Studies

  • What is an Investigational New Drug or IND Program?

    The purpose of IND-enabling studies is to secure approval to conduct the first-in-human clinical trials with a new drug. An IND application contains information on pharmacology and toxicology, manufacturing (e.g., composition, production, stability, etc.), human clinical study protocols, and investigator information. At Charles River, we focus primarily on the pharmacology and toxicology testing, which is designed to provide evidence that the drug has its intended effect and that the proposed human dose levels are safe.

  • Why is an IND application required?

    The United States Food and Drug Administration (FDA) requires that an IND application be submitted in order to determine if the efficacy and safety profile, the proposed manufacturing process, and the clinical trial designs of a new drug are acceptable to allow for studies in humans. An IND program and application compiles all this information, which facilitates regulatory review. Once an IND application is submitted, the FDA has 30 calendar days to review the package. Unless the FDA indicates otherwise, the IND sponsor is free to initiate the proposed human studies once the 30 days have elapsed.

  • What studies are required as part of an IND program?

    To support IND-enabling studies, nonclinical (i.e., “non-human”) studies are conducted to evaluate the efficacy and safety of the drug. The pharmacology studies most often consist of in vitro (cellular) and in vivo (whole animal) studies that demonstrate that the new drug binds to its intended target and has the desired effect. This is often done in animal models that mimic the human disease. Once proof-of-concept is demonstrated in the pharmacology studies, the nonclinical safety studies (i.e., the toxicology studies) evaluate the safety profile of the drug. This includes profiling the drug’s effect on DNA (genotoxicity), critical organ systems (i.e., cardiovascular, respiratory, and central nervous system effects through safety pharmacology), and general toxicity (through animal studies in rodent and nonrodent species). During the IND-enabling studies, the collected data will demonstrate systemic exposure to the drug, the exposures and nature of adverse effects at high dose levels, and the safety margin (i.e., the margin between doses/exposures associated with efficacy and doses/exposures associated with toxicity).